ArticleSpringerPlus2016

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.

Katharina Gunzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.